AbbVie Inc. (NYSE:ABBV) saw a downside of -0.70% to close Monday at $148.55 after subtracting -$1.04 on the day. The 5-day average trading volume is 7,308,660 shares of the company’s common stock. It has gained $155.10 in the past week and touched a new high 1 time within the past 5 days. An average of 5,409,005 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,534,488.
ABBV’s 1-month performance is -7.49% or -$14.55 on its low of $147.15 reached on 01/20/23. The company’s shares have touched a 52-week low of $128.26 and high of $175.91, with the stock’s rally to the 52-week high happening on 01/06/23. YTD, ABBV has lost -8.08% or -$13.06 and has reached a new high 4 times. However, the current price is down -15.55% from the 52-week high price.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ABBV stock investors last saw insider trading activity on Dec 12.RICHMOND TIMOTHY J. (EVP, CHIEF HR OFFICER) most recently sold 42,370 shares at $163.44 per share on Dec 12. This transaction cost the insider $6,925,018. Vice Chairman, SEVERINO MICHAEL, sold 79,801 shares at a price of $150.90 on May 23. Then, on May 17, Vice Chairman SEVERINO MICHAEL sold 100,000 shares at a price of $154.04 per share. This transaction amounted to $15,404,400.
ABBV stock has a beta of 0.61. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.52 while the price-to-book (PB) in the most recent quarter is 16.45, with the price to cash flow ratio at 21.64.
AbbVie Inc.’s quick ratio for the period ended June 29 was 0.80, with the current ratio over the same period at 0.90. As well, the company’s long term debt to equity for the quarter ending June 29 was 3.78, while the total debt to equity was 4.35. In terms of profitability, the gross margin trailing 12 months is 71.20%. The firm’s gross profit as reported stood at $38.75 billion against revenue of $56.2 billion.
For the quarterly period ending June 29 this year, AbbVie Inc.’s cash and short-term investments amounted to $47.0 million against total debt of $73.19 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 19.5% to $3.95 billion, while revenue of $924.0 million was 76.6% off the previous quarter. Analysts expected ABBV to announce $3.31 per share in earnings in its latest quarter, but it posted $3.37, representing a 1.80% surprise. EBITDA for the quarter stood at more than $6.81 billion. ABBV stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 125.3 billion, with total debt at $73.19 billion. Shareholders hold equity totaling $1.77 billion.
Let’s look briefly at AbbVie Inc. (ABBV) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 24.80% to suggest the stock is trending oversold, with historical volatility in this time period at 18.32%.
The stock’s 5-day moving average is $149.78, reflecting a -3.29% or -$5.05 change from its current price. ABBV is currently trading -8.42% above its 20-day SMA, +9.46% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +0.01% and SMA200 by-9.10%.
Stochastic %K and %D was 8.32% and 6.68% and the average true range (ATR) pointed at 3.16. The RSI (14) points at 30.48%, while the 14-day stochastic is at 6.68% with the period’s ATR at 3.13. The stock’s 9-day MACD Oscillator is pointing at -3.44 and -7.43 on the 14-day charts.
In the most recent analyst report for AbbVie Inc. (NYSE: ABBV), Credit Suisse launched coverage with an Outperform rating. Analysts offering their rating for ABBV stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate ABBV as a “sell,”, while 11 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 13 have offered a “buy” rating.
What is ABBV’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $135.00 and a high of $200.00, with their median price target at $163.55. Looking at these predictions, the average price target given by analysts is for AbbVie Inc. (ABBV) stock is $163.10.